Bicara Therapeutics Common Stock Today
| BCAX Stock | 13.24 0.15 1.15% |
PerformanceVery Weak
| Odds Of DistressAbout Average
|
Bicara Therapeutics is trading at 13.24 as of the 24th of March 2025; that is 1.15 percent up since the beginning of the trading day. The stock's open price was 13.09. Bicara Therapeutics has 50 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 24th of March 2025. Click here to learn more.
Moving against Bicara Stock
Follow Valuation Daily Balance Of Power
Check how we calculate scores
Bicara Stock Highlights
| CEO Director | Claire MBA |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) |
Bicara Therapeutics Common (BCAX) is traded on NASDAQ Exchange in USA. It is located in 116 Huntington Avenue, Boston, MA, United States, 02116 and employs 10 people. Bicara Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 900.58 M. Bicara Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 54.39 M outstanding shares of which 4.17 M shares are currently shorted by private and institutional investors with about 0.0 trading days to cover.
Bicara Therapeutics generates negative cash flow from operations
Check Bicara Therapeutics Probability Of Bankruptcy
Ownership AllocationBicara Therapeutics holds a total of 54.39 Million outstanding shares. Almost 99.58 percent of Bicara Therapeutics outstanding shares are held by general public with 0.42 (percent) owned by insiders and only 0.0 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Bicara Ownership Details
Bicara Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Bicara Therapeutics market risk premium is the additional return an investor will receive from holding Bicara Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.08) | |||
| Jensen Alpha | (0.46) | |||
| Total Risk Alpha | (0.11) | |||
| Treynor Ratio | (4.47) |
Bicara Stock Against Markets
Bicara Therapeutics Corporate Management
| Angela Windt | VP Affairs | Profile | |
| Rachel Salazar | SVP Operations | Profile | |
| MD MBA | Senior Affairs | Profile | |
| Lara JD | Chief Secretary | Profile | |
| JeanPaul Rodrique | Senior Assurance | Profile | |
| Sathish Hasige | Senior Chain | Profile |
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.